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Abstract 
Background: The ‘BOADICEA’ Web Application (BWA) used to assess breast cancer risk, is currently being 
further developed, to integrate additional genetic and non-genetic factors. We surveyed clinicians’ 
perceived acceptability of the existing BWA v3. 
Methods: An online survey was conducted through the BOADICEA website, and the British, Dutch, 
French and Swedish genetics societies. Cross-sectional data from 443 participants who provided at least 
50% responses were analysed. 
Results: Respondents varied in age and, clinical seniority, but mainly comprised women (77%) and 
genetics professionals (82%). Some expressed negative opinions about the scientific validity of BOADICEA 
(9%) and BWA v3 risk presentations (7-9%). Data entry time (62%), clinical utility (22%) and ease of 
communicating BWA v3 risks (13-17%) received additional negative appraisals. 
In multivariate analyses, controlling for gender and country, data entry time was perceived as longer by 
genetic counsellors than clinical geneticists (p<.05). Respondents who (1) considered hormonal BC risk 
factors as more important (p<.01), and (2) communicated numerical risk estimates more frequently 
(p<.001), judged BWA v3 of lower clinical utility. Respondents who carried out less frequent clinical 
activity (p<.01) and respondents with ‘11 to 15 years’ seniority (p<.01) had less favourable opinions of 
BWA v3 risk presentations. Seniority of ‘6 to 10 years’ (p<.05) and more frequent numerical risk 
communication (p<.05) were associated with higher fear of communicating BWA v3 risks to patients. The 
level of genetics training did not affect opinions. 
Conclusion: Further development of the BWA should consider technological, genetics service delivery 
and training initiatives. 
 
Keywords: Breast cancer, risk prediction model, tool, appraisal, clinical practice, survey 
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Introduction 
Breast cancer (BC) is a major public health problem for women with almost 1.7 million new BC 
diagnoses estimated worldwide in 2012 [1]. Among these BC patients, 10 to 20% present with a BC 
family history, and two decades ago, BRCA1 and BRCA2 were identified as major BC susceptibility genes 
[2]. Recently, additional genetic factors have been identified, including rare variants in genes other than 
BRCA1 and BRCA2 associated with “moderate” to “high” risk of BC, and common genetic variants which 
individually are associated with low BC risk [3]. 
Next-generation sequencing, whole-exome and whole-genome sequencing, and “gene panel 
testing” are recent technological advances that allow far more genes to be simultaneously tested than 
BRCA1 and BRCA2 alone, at a reduced cost and a faster turn-around. As a result, gene panel testing has 
entered oncology genetic services. These panels include a variable number of genes [4-6] and clear 
evidence of association with breast cancer is currently available for eleven genes (i.e., BRCA1, BRCA2, 
TP53, PALB2, PTEN, CHEK2, ATM, NF1, PTEN, STK11, CDH1) [7].  
This study was performed as part of the BRIDGES research program [8] that aims to implement 
comprehensive genetic testing into BC risk assessment. The latter will be achieved through further 
development of the ‘Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm’ 
(BOADICEA) which presently computes BRCA1 and BRCA2 mutation carrier probabilities and future risks 
of developing breast and ovarian cancer on the basis of explicit disease inheritance patterns, family 
history and genetic testing information [9-13].  
The BOADICEA model and BOADICEA Web Application version 3 (BWA v3, 
http://ccge.medschl.cam.ac.uk/boadicea/boadicea-web-application/) also allow for demographic factors 
and tumour pathology information such as the oestrogen and progesterone receptors, HER2, CK5/6, 
CK14 status of BC in family member(s) to be taken into account [12].  
BWA v3 was released for general use to the healthcare community in February 2014, and had 
been in widespread use for over two years at the time this survey was conducted. As a result, the survey 
respondents' views principally reflect their experience of using BWA v3 in clinical practice. In April 2016 
(one month before the start of the survey), BWA v4 was released (currently under beta-testing) which 
included the effects of truncating mutations in PALB2, CHEK2 and ATM [13]. Within BRIDGES, the 
BOADICEA model will be extended to include additional known breast cancer susceptibility genes.  
4 
 
The clinical acceptability of the BOADICEA model and BWA v3 need to be evaluated to inform 
further development. In practice, several factors have been shown to hamper the clinical 
implementation of BC risk decision support tools [14] including: (1) logistic barriers (e.g. time required to 
use BWA v3), (2) clinical barriers (e.g. beliefs in personal clinical intuition against trust in the tool’s 
usefulness [15]), and (3) educative barriers (e.g. skills needed to understand numerical risk estimates and 
to communicate them to patients [16]). 
Although reservations have been expressed with regard to the use of the BWA in clinical 
practice, to our knowledge, no large quantitative report is yet available. Such data would inform the 
further development of this tool and help to address the needs of clinical users.  
The present study addressed the following research questions:  
1. How acceptable for clinical use is the BWA v3 in terms of clinicians’ assessment of data entry 
timing, clinical utility, presentation and ease of communicating cancer risks? 
2. To what extent are these considerations affected by the user’s profession, weekly clinical genetic 
activity level, clinical seniority, specific genetics training attendance, importance attributed to BC 
modifying risk factors and tendency to communicate risk numerically? 
 
Methods 
This was a cross-sectional study.  
The overall survey content and example of questions are provided in table 1. The survey included 
four sections addressing: 1) Practice in genetic counselling and testing for cancer predisposition (14 
questions); 2) Importance attributed to BC risk factors, including modifying BC risk factors; BWA v3 
frequency of use and data entry time; ways of communicating risk (i.e., in relative, absolute, absolute 
over 5, 10 or 15 year forms) (26 questions); 3) BWA v3 aspects’ assessment (13 questions); and 4) Socio-
demographic and professional background (8 questions) (Supplementary material).     
 
Insert Table 1 about here 
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Survey development 
The questionnaire was developed in line with BRIDGES’ objectives, which specified the 
assessment of the BOADICEA model and BWA v3 acceptability in clinical practice. Two questionnaires 
were identified from published studies addressing similar objectives: a study-specific questionnaire 
developed to assess clinicians’ views of BC risk prediction models [17] and two validated instruments to 
assess clinicians’ perceived usability and satisfaction with a decision aid for women carrying a BRCA1 or 
BRCA2 mutation [18]. These were adapted, thus providing a 9-item questionnaire addressing the 
perceived clinical utility of BWA v3, risk estimates presentation and ease of communication [18] and a 4-
item questionnaire designed to assess how BWA v3 risk estimates might impact clinical judgement in 
practice [17] (see Table 3 in the results section). 
  A preliminary version of the overall survey was designed following survey methods 
recommendations [19, 20]. It was pilot-tested with clinical geneticists, genetic counsellors, 
gynaecologists, psycho-oncologists, a radiotherapist and a methodologist (n=21). 
 
Online participants’ recruitment 
An online survey involving one reminder was conducted using the LimeSurvey application 
(http://www.limesurvey.org) [21] during May to September 2016.  
First, the survey targeted clinicians who were among the potential 7,500 individuals who 
registered to use the BWA since 2007. Second, in order to reach potential non-users of the BWA from 
genetic clinics, BRIDGES investigators were solicited to contact members of their National Genetics 
Societies (NGS) who were also invited to complete the survey. A total of 225, 170, 37 and 32 individuals 
were contacted from the British, French, Dutch and Swedish NGS, respectively. 
 
Data analysis 
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As shown in figure 1, 525 and 203 respondents’ data were extracted from the BWA and NGS 
survey sources respectively. The response rate obtained from the BWA survey source could not be 
estimated as the survey was sent to registered individuals who might no longer use the tool, and tracking 
BWA v3 use is not legally permitted. Among respondents contacted through NGS, the response rate was 
43.7% (203 respondents out of 464 NGS members, excluding those who responded through the BWA 
website). 
 
Insert Figure 1 about here 
 
As indicated in Table 1, we developed indicators of genetic clinical activity level, importance 
attributed to modifying BC risk factors (i.e., reproductive, lifestyle, hormonal and body mass index), and 
for the BWA v3 appraisals. Higher scores on the three BWA v3 appraisal variables reflect favourable 
opinions. 
Responses were reported in frequencies (percentages). Associations between BWA v3 data entry 
time and frequency of use (occasionally, regularly, always) were assessed using Chi2 tests.  
We performed multivariate linear regression analyses [22] for the continuous variables including 
the BWA v3 perceived data entry timing, estimates of clinical utility, risk presentation and ease of risk 
communication. Professional background characteristics, importance attributed to modifying BC risk 
factors and mode of numerical risk communication were explored as potential explanatory variables. We 
controlled for clinicians’ gender and country of practice. Age was significantly correlated to respondents’ 
clinical seniority so to maintain parsimony it was not included as an explanatory variable. Correlation 
coefficients between risk communication modes (i.e., using relative, absolute, absolute over 5, 10 or 15 
year figures) ranged from 0.15 to 0.36. As the absolute figure mode presented the highest correlation 
with BWA v3 use frequency (r=0.20), only this mode was included as an explanatory variable. 
Statistical analyses were performed with R software version 3.3.1 [23]. 
 
Results 
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Overall, 443 respondents completed at least 50% of the survey, comprising 316 (71.3%) and 127 
(28.7%) through the BWA and NGS survey, respectively (Figure 1). Successive survey sections were 
gradually less frequently completed, and as a consequence, there were fewer data for the last section 
addressing respondents’ socio-demographic and professional characteristics (N=394). 
 
Sample characteristics 
As shown in table 2, a wide range of countries were represented among respondents, including 
France (22%), United Kingdom (20%), Western European countries (other than France and Germany) 
(13%), USA (12%), Australia and Germany (8%), Canada, Southern European and other countries (6%). 
Respondents also varied by age and years of clinical experience but were mainly female (77%) and most 
declared completion of genetics training (e.g., master’s degree in genetic counselling, clinical genetics, 
residency/internship experience, conference attendance) (70%).  
 
Insert Table 2 about here 
 
BOADICEA Web Application appraisals and data entry time 
Less than 10% of respondents expressed negative opinions on 5 out of 9 items addressing BWA v3 
aspects. Some expressed negative opinions about the scientific validity of BOADICEA (9%) and BWA v3 
risk presentations (7-9%). Data entry time (62%) and estimates of clinical utility (22%) received additional 
negative appraisals. Moreover, a significant minority of respondents expressed fear of patients’ 
misunderstanding (17%) and fear of upsetting patients (13%) using BWA v3 in clinical practice.  
About half of respondents indicated that the risk estimates would not change their clinical 
judgement about breast or ovarian cancer risk management (Table 3). 
The overall mean time (standard deviation) taken for data entry using BWA v3 was 15.5 (10.9) 
minutes (data not shown). The data entry time was not associated with frequency of use, or with 
whether the respondent was a clinical geneticist, a genetic counsellor or another clinician (Table 4). 
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Insert Table 3 and 4 about here 
 
Predictors of BOADICEA Web Application appraisals  
In multivariate analyses, data entry time using BWA v3 was perceived as longer by genetic 
counsellors than clinical geneticists (p<0.05). BOADICEA clinical utility was perceived less favourably with 
increasing importance given to hormonal BC risk factors (p<0.01) and for its feature to communicate 
numerical risk estimates (absolute figure) (p<0.001) (Table 5).  
Respondents who reported more frequent weekly genetic clinical activity had more positive 
opinions regarding BWA v3 risk presentations (p<0.01). In this respect, compared to respondents with 
‘less than 6 years’ clinical seniority, those with a ‘11 to 15 years’ seniority expressed more negative 
opinions (p<0.01).  
Greater ease of risk communication using BWA v3 was expressed by respondents with 
intermediate ‘6 to 10 years’  level of seniority compared to those with ‘less than 6 years’ (p<0.05). 
Numerical (absolute figure) BC risk communication was associated with greater ease of BC risk 
communication using BWA v3. 
Data entry time using BWA v3 was perceived as shorter by men (p<0.01) compared to women. In 
addition, data entry was perceived as longer by respondents from Australia (p<0.05), France (p<0.05), 
Germany (p<0.001), and Southern and Western European countries (p<0.01), compared to those from 
the UK. Compared to the UK, respondents from Australia and the US judged the BWA v3 clinical utility 
more favourably. Ease of risk communication using BWA v3 was perceived as less positive by French 
(p<0.001) but more positive by US respondents (p<0.01) compared to UK participants.  
 
Insert Table 5 about here 
 
Discussion 
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The BOADICEA model is being developed further to include all known genetic and non-genetic BC risk 
factors. In parallel, the BWA is being modified to fulfil more closely clinicians’ and patients’ 
requirements. In this study we performed an online survey to assess clinicians’ appraisals of BWA v3, and 
their professional background and practice correlates.  
Besides BOADICEA, there are many other BC genetic risk prediction tools available for clinical 
practice through web-based interfaces. Examples are the BRCAPRO [24, 25] or IBIS [26, 27]. To our 
knowledge, the use and acceptance of these among clinicians has not yet been systematically studied. 
Currently, BOADICEA incorporates high and intermediate-high risk mutations, BC pathology, family 
history of prostate or pancreatic cancer as well as data from relatives of any degree of relatedness [3]; 
the implementation of comprehensive BC risk assessment, including hormonal, lifestyle and reproductive 
factors in the near future, should improve its clinical utility substantially. 
Survey participants from various countries favourably appraised the scientific validity of the 
BOADICEA model and BWA v3 risk presentations. Few respondents (9%) expressed that the BOADICEA 
model was not sufficiently validated. This reflects an awareness, amongst BWA v3 users, of studies that 
describe the performance of the model in predicting the likelihood of carrying a BRCA1 or BRCA2 
mutation [28] or the risk of developing breast or ovarian cancer [11, 29] in different populations. 
However, a number of respondents (22%) thought that their clinical judgment was as good as or 
better than BOADICEA risk estimates. Moreover, about half of respondents stated that BOADICEA risk 
estimates would not change their clinical judgement on breast or ovarian cancer risk management. Less 
favourable opinions on the clinical utility of BWA v3 may be partly explained by: (1) inconsistencies in 
clinical guidelines between different BC risk prediction models or timeframes [29]; (2) the fact that BWA 
v3 does not link computed risks with specific clinical recommendations; or (3) insufficient information 
provided by the model (e.g., to predict BC risk after prior surgery). On-going extensions to the BOADICEA 
model and BWA are expected to address these limitations.   
Lower perceived clinical utility of BWA v3 was expressed with increasing importance given to 
hormonal BC factors such as hormone replacement therapy. The current BOADICEA model does not 
include these factors in contrast to the Gail and IBIS models [3] but on-going extensions will also include 
known lifestyle and hormonal risk factors. We note that the absence of other BC risk-modifying factors in 
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the BOADICEA model did not affect respondents’ appraisal of its clinical utility which suggests a training 
requirement with regard to the role of factors, such as those related to lifestyle, affecting BC prevention 
[30].   
Respondents who tended to express risk as numerical figures also perceived BWA v3 clinical 
utility less positively. It may be that numerical figures (i.e integers between 0 and 100) provide less 
latitude for clinical interpretation than broad risk categories expressed as words (i.e., moderate, high, 
very high). 
Sixty two percent of respondents perceived that the time required for data entry using BWA v3 
was too long. This is expected as, compared to other BC risk prediction models, BOADICEA considers 
additional BC risk factors [3, 31] and can accommodate large families [9] (BWA v3 can accommodate up 
to 275 family members). We expected that increased frequency of use of BWA v3 could result in shorter 
data entry times through improved skills, but this was not observed in this study. However, controlling 
for gender and country of practice, the time for data entry was perceived as longer by genetic 
counsellors than clinical geneticists. This difference may be related to role sharing between medical and 
non-medical genetics clinicians.  
The time required for data entry using BWA v3 partly reflects the design of the software. BWA v3 
captures input pedigree data using HTML forms (form-based data entry). However, it is clear that 
graphical pedigree data entry programs (that enable users to create a pedigree drawing, with small 
forms to enter data for each family member) can often capture pedigree data sets more quickly and 
easily than form-based programs such as BWA v3. The first version of the BWA was released for general 
use to the healthcare community in 2007. Since that time, advances in client-side software development 
technologies have facilitated the implementation of Web-based graphical pedigree building tools, and so 
the BWA will be extended to include such tools in the future. In addition, the time required for data 
entry using BWA v3 also partly reflects the data requirements of the underlying BOADICEA model (e.g., 
BWA v3 requires that the user specifies a year of birth in order for a family member to be taken into 
account in a risk calculation, whereas the IBIS tool does not). 
Respondents who reported a more frequent genetic clinical activity judged BWA v3 risk 
presentations more positively. However, compared to a clinical experience of less than 6 years, 
11 
 
respondents with ‘11 to 15 years’ seniority expressed less positive appraisals of BWA v3 risk 
presentations. A non-significant trend in this relationship was also revealed for longer seniority. 
To be used in clinical practice, a risk assessment tool must present risk estimates in such a way 
that they are not only easy to understand, but also easy to communicate to patients. Respondents more 
inclined to communicate risk in numerical format reported that it was easier to communicate risk using 
BWA v3. Clinicians presenting risk information as numbers rather than words may possibly feel more 
adequately understood [32].  
Respondents with a clinical experience of ‘6 to 10 years’ reported that it was easier to 
communicate risks using BWA v3 than those who had a clinical experience of less than 6 years. This may 
be due to the combination of higher than 6 years clinical experience with more recent genetics training 
than beyond 10 years. 
Compared to respondents from the UK, risk communication using BWA v3 was found to be 
easier for US respondents but more difficult for French users. The effect of country of practice is difficult 
to explain in this study. Clinicians from the US have reported positive experiences using the BRCA tool 
[33] with women carrying a BRCA1 or BRCA2 mutation [18]. However, in some cultures, the use of direct 
presentation of cancer risk figures and curves in clinical practice may be found less acceptable as it 
suggests clinicians’ fear of causing increased counselees’ cancer-specific anxiety. Providing information 
on cancer risk is complex both cognitively and emotionally. In a recent US survey on communication skills 
which involved non-genetic clinicians, managing patients’ emotions was found to be mostly difficult [34], 
which underlines the importance of devoting time for this aspect in cancer genetics training. 
 
Study limitations and strengths  
The study has several limitations. The sample is self-selected based on willingness to participate 
and over-represents BWA users. NGS from only four countries were solicited; this resulted in a 
disproportional number of respondents’ from the UK and French NGS compared to other countries. 
However, the overall sample was large which allowed for multivariate analyses to be performed. 
Participants varied in age, country of practice and years of experience so a wide range of clinicians 
provided their opinions.  
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Although genetics health professionals are currently the main targeted users of the BWA, further 
survey addressing BWA clinical use should strive to reach non-genetic clinicians such as breast surgeons, 
oncology specialists and general practitioners who will be increasingly involved in BC risk counselling 
[35].  
Conclusions 
This international survey revealed that the BWA is mostly valued by health professionals’ using 
it. However, considering that further BOADICEA development plans to include additional factors, to 
facilitate uptake of the BWA in clinical practice, technological (e.g., step-wise assessment), organisational 
initiatives (e.g., involving patients or non-genetic professionals such as a nurse navigator [35]) and 
training initiatives should also be considered. We intend to repeat this survey when the new version of 
the BWA becomes available to monitor its acceptability. 
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